Join the Semaglutide group to help and get support from people like you.
Semaglutide News (Page 2)
Senators Call on FDA to Act Against Misleading Weight-Loss Drug Commercials
WEDNESDAY, Feb. 12, 2025 – Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out advertisement of prescription of injectable...
Can GLP-1 Meds Harm Your Eyes?
MONDAY, Feb. 10, 2025 – Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on whether the medications caused the eye trouble, according...
New Facial Plastic Surgery Survey Illustrates Impact of GLP-1 Receptor Agonists
FRIDAY, Feb. 7, 2025 – Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the field of facial plastic surgery, according to the results of...
Prescriptions for Obesity Management Drugs Increasing
THURSDAY, Feb. 6, 2025 – Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with online search trends, according to a study published online...
FDA Approves Ozempic (semaglutide) as the Only GLP-1 RA to Reduce the Risk of Worsening Kidney Disease and Cardiovascular Death in Adults with Type 2 Diabetes and Chronic Kidney Disease
PLAINSBORO, N.J., Jan. 28, 2025 /PRNewswire/ – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Ozempic to reduce the risk of kidney disease worsening,...
Several Factors Play Role in Semaglutide Initiation for Obesity Without Diabetes
THURSDAY, Jan. 23, 2025 – Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes, according to a study published...
Websites Selling Compounded GLP-1 RAs Often Misinform Consumers
TUESDAY, Jan. 21, 2025 – Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers, including with respect to U.S. Food and...
The New Definition of Obesity
The way obesity is diagnosed needs to become more sophisticated, an international commission has concluded. Using body-mass index (BMI) to tell who is overweight or obese is not reliable, and can...
Perioperative GLP-1 RA Use Reduces Risk for Complications in Patients With Diabetes
MONDAY, Jan. 13, 2025 – For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with...
Semaglutide Doubles Risk for Nonarteritic Anterior Ischemic Optic Neuropathy
TUESDAY, Jan. 14, 2025 – Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, according to a...
Some GLP-1s Achieve More Weight Loss Than Others: Study
WEDNESDAY, Jan. 8, 2025 – Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been approved for that purpose. A new evidence review published ...
GLP-1 RAs Efficacious for Weight Loss in Overweight, Obesity Without Diabetes
TUESDAY, Jan. 7, 2025 – For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious for weight loss, according to a review published...
GLP-1 RAs Reduce Risk for Clinically Important Kidney, CVD Outcomes
FRIDAY, Dec. 6, 2024 – Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk for clinically important kidney and cardiovascular disease outcomes in individuals with type 2 diabetes,...
New Weight-Loss Advance: A Gastric Balloon You Control to Feel Full or Not
TUESDAY, Dec. 3, 2024 – GLP-1 meds are all the rage for weight loss nowadays, but not everyone can safely take the drugs to shed pounds. Invasive weight-loss surgeries can often be a tough sell,...
American Heart Association, Nov. 16-18
The annual meeting of the American Heart Association was held this year from Nov. 16 to 18 in Chicago, drawing attendees from around the world, including cardiovascular specialists, surgeons, and n...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Cardiovascular Risk Reduction, Chronic Kidney Disease, Diabetes, Type 2